Categories: News

Overview of the deadlines at which shares of AS Olainfarm will be excluded from the regulated market:

Overview of the deadlines at which shares of AS Olainfarm will be excluded from the regulated market:

  1. The period of the share buy-back offer began on 08.11.2021.
  2. The period of the share buy-back offer will end on 07.12.2021.
  3. Within 5 working days (until 14.12.2021.), a report on the results of the share buy-back offer will be published in the official publication Latvijas Vēstnesis and payments of shares will be made with shareholders that have accepted the share buy-back offer.
  4. Not earlier than 10 (until 29.12.2021.) and not later than 15 working days (until 06.01.2022) from the date on which the report on the results of the offer was published in the official publication Latvijas Vēstnesis AS Olainfarm will submit an application to the Nasdaq Riga stock exchange regarding the exclusion of shares from the stock exchange.
  5. Within 10 working days (until 20.01.2021.) management board of the Nasdaq Riga stock exchange will take a decision on the exclusion of the shares of AS Olainfarm from the stock exchange.

Additional information:  
Jānis Leimanis
JSC Olainfarm Member of Management Board
Phone: +371 29269424
Email: janis.leimanis@olainfarm.com

Staff

Recent Posts

Restart Life Closes Over-Subscribed Second Tranche Financing

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

50 minutes ago

BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc.…

50 minutes ago

Akanda Corp. Welcomes Momentum Towards Cannabis Reform in the United States

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company")…

50 minutes ago

Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.

Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025Toronto, Ontario--(Newsfile Corp. -…

50 minutes ago

Optimi Health Announces Appointment of New Director

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX:…

2 hours ago

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke…

3 hours ago